Navigating Non-Small Cell Lung Cancer Treatments with Dr. Eric Singhi | 02.17.26 | Living Room® Full

Join Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer , for an insightful Lung Cancer Living Room conversation with Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson Cancer Center.In this episode, Dr. Singhi breaks down the rapidly evolving landscape of non-small cell lung cancer (NSCLC) treatments. From the latest targeted therapies to the importance of being an active partner in your healthcare journey, this comprehensive discussion is designed to help patients and care partners make informed decisions. Key Topics Covered in This Episode:The Power of Biomarker Testing: Discover why comprehensive molecular testing—using both tissue and liquid (blood) biopsies—is the "name of the game" for personalizing treatment plans at both early and advanced stages.Understanding ADCs: Learn about Antibody Drug Conjugates (ADCs), a targeted approach Dr. Singhi refers to as "smart chemo," designed to deliver a high dose of treatment directly to cancer cells.Local Consolidative Therapy (LCT): Explore how combining systemic drugs with local treatments like surgery or radiation can help control stage IV disease, highlighting research like the Northstar trial for EGFR-positive patients.Clinical Trials as a Priority: Dispelling the myth that trials are a "last resort," Dr. Singhi explains why they should be discussed at every step of the cancer journey.Patient Empowerment: Actionable advice on how to communicate side effects early, navigate second opinions, and why bringing a care partner to appointments is vital for remembering complex information.Whether you are newly diagnosed, experiencing a progression, or caring for a loved one, this conversation is packed with hope, guidance, and the tools you need to advocate for the best possible care. 00:00 Introduction & Welcome 02:33 Dr. Eric Singhi’s Background & Focus on Lung Cancer 04:15 The Main Treatment Options for NSCLC 05:58 Determining the Best Treatment Plan 06:51 How Treatments Differ Based on Stage (Cure vs. Control) 09:27 The Importance of Biomarker Testing 12:06 Liquid vs. Tissue Biopsies 13:31 When Should Biomarker Testing Be Done? 15:54 Using Liquid Biopsies to Monitor or Reduce Medication 17:44 How Biomarkers Determine the Treatment Plan 20:09 Biomarker Testing and Immunotherapy Eligibility 20:10 Taking a Break or Reducing Doses of Targeted Therapies 24:20 The Crucial Role of Re-Biopsy at Progression 26:06 Dealing with Insurance Pushback 28:09 Microscopic vs. Macroscopic Disease 30:00 Early-Stage Treatment Decisions & Tumor Boards 32:21 Combination Therapies & Local Consolidative Therapy (LCT) 35:46 Attacking the "Mothership" in Stage IV 37:37 Do LCT Trials Extend Beyond EGFR Patients? 38:51 Treatment Options for Patients Without Targetable Biomarkers 41:35 Understanding Antibody-Drug Conjugates (ADCs) 43:29 Why It Is Crucial to Report Side Effects Early 44:48 How to Talk to Your Doctor About Second Opinions 48:21 Balancing Information Overload 53:21 Patient Empowerment & Better Outcomes 55:06 The Vital Role of Care Partners in Medical Appointments 56:55 Dr. Singhi's Message of Hope & Key Takeaways